|
KMID : 0364320180430010001
|
|
Journal of East-West Medicine
2018 Volume.43 No. 1 p.1 ~ p.18
|
|
|
The Merge Effect of a Combination of Sulfasalazine and Curcumae Radix and Bupleuri Radix Mixture in DSS-induced Colitis Mice
|
|
Kim Su-Min
Shin Hyeon-Cheol
Jin Diong-Eun
|
|
|
Abstract
|
|
|
Objectives：Sulfasalazine, which has used as a standard care for treatment of inflammatory bowel disease (IBD) for decades, potentially has severe adverse effects after high dosage and long term intake. The present study aimed to investigate the comparative evaluation of pharmacological efficacy between sulfasalazine alone and a combination with herbal medicine on dextran sodium sulfate (DSS)-induced ulcerative colitis (UC) in mice.
Materials and Methods : Balb/c mice received 5% DSS in drinking water for 7 days to induce colitis. Animals were divided into five groups (n = 9): group I-normal group, group II-DSS control group, group III-DSS + sulfasalazine (30 ㎎/㎏ group IV-DSS + sulfasalazine (60 ㎎/㎏), group V-DSS + sulfasalazine (30 ㎎/㎏) + Curcumae Radix and Bupleuri Radix mixture (30 ㎎/㎏) (CBM). Colonic pathological changes were analized using hematoxyline/ eosin staining. The anti-oxidant, inflammatory, and apoptotic protein levels were determined using western blotting.
Results : DSS-treated mice developed symptoms similar to those of human UC, such as severe bloody diarrhea and weight loss. CBM supplementation, as well as sulfasalazine, suppressed colonic length shortening and mucosal inflammatory infiltration. In addition, CBM treatment significantly reduced the expression of pro-inflammatory signaling molecules through suppression of nuclear factor-kappa B (NF-κB) signaling pathways, and prevented the apoptosis of colon. Moreover, CBM administration significantly led to the up-regulation of anti-oxidant enzyme including SOD, Catalase, and GPx-1/2.
Conclusion : This is the first report that CBM combined with sulfasalazine protects against experimental UC via the inhibition of both inflammation and apoptosis, very similar to the standard-of-care sulfasalazine. We suggest that CBM administration might offer a better treatment for human UC than sulfasalazine alone, or may be useful as an alternative therapeutic strategy against UC, without any evidence of side effects.
|
|
|
KEYWORD
|
|
|
Dextran sodium sulfate, ulcerative colitis, sulfasalazine, Curcumae Radix and Bupleuri Radix mixture, NF-κB
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|